IDO1 and neoplasm: A phase I trial of tumor patients using Indoximod as an IDO1 inhibitor has shown that doses higher than 1,200 mg 1-MT in a patient do not increase peak serum levels over ~16 μM (26), indicating a limited accumulation of the applied inhibitor.